Cardiovascular function in HER2-postivie breast cancer survivors
Background: Trastuzumab, a HER2 antagonist, has been shown to improve rates of overall survival in patients with HER2-positive breast cancer. However, cardiotoxic effects associated with treatment limits these benefits. Due to an increase in survival years, women with a history of HER2-positive brea...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2014
|
| Online Access: | http://hdl.handle.net/2429/50924 |